|
XANTHINES WHEN CONCOMITANTLY USED WITH HALOTHANE OR KETAMINE MAY HAVE INCREASED RISK OF SYNERGISTIC TOXICITY & MAY CAUSE CARDIAC ARRHYTHMIAS
|
XANTHINES WHEN CONCOMITANTLY USED WITH HALOTHANE OR KETAMINE MAY HAVE INCREASED RISK OF SYNERGISTIC TOXICITY & MAY CAUSE CARDIAC ARRHYTHMIAS
|
OMEPRAZOLE DELAYS ELIMINATION OF THE DRUG
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
|
INTERCONVERSION BETWEEN CAFFEINE AND AMINOPHYLLINE HAS BEEN REPORTED IN PRETERM NEONATES ; THE CONCURRENT USE OF THESE DRUGS IS NOT RECOMMENDED
|
POTENTIAL FOR SEVERE AND FATAL REACTIONS INCLUDING CARDIAC ARREST, SEIZURES, RESPIRATORY FAILURE AND STATUS EPILEPTICUS ; CONCURRENT USE SHOULD BE AVOIDED OR SERUM LEVELS OF THEOPHYLLINE SHOULD BE MONITORED CAREFULLY
|
POTENTIAL FOR SEVERE AND FATAL REACTIONS INCLUDING CARDIAC ARREST, SEIZURES, RESPIRATORY FAILURE AND STATUS EPILEPTICUS ; CONCURRENT USE SHOULD BE AVOIDED OR SERUM LEVELS OF THEOPHYLLINE SHOULD BE MONITORED CAREFULLY
|
CO-ADMINISTRATION IN PATIENTS WHO ARE RECEIVING HIGH DOSES OF THEOPHYLLINE MAY BE ASSOCIATED WITH AN INCREASE IN SERUM THEOPHYLLINE LEVELS AND POTENTIAL THEOPHYLLINE TOXICITY
|
OMEPRAZOLE DELAYS ELIMINATION OF THE DRUG
|
OMEPRAZOLE DELAYS ELIMINATION OF THE DRUG
|
POTENTIAL FOR SEVERE AND FATAL REACTIONS INCLUDING CARDIAC ARREST, SEIZURES, RESPIRATORY FAILURE AND STATUS EPILEPTICUS ; CONCURRENT USE SHOULD BE AVOIDED OR SERUM LEVELS OF THEOPHYLLINE SHOULD BE MONITORED CAREFULLY
|
THEOPHYLLIN POTENTIATES ITS METABOLISM , HENCE SERUM CONCENTRATION IS DECREASED
|
XANTHINE DERIVATIVES SHOULD BE AVOIDED IN PATIENTS WITH ORGANOPHOSPHATE POISONING
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
ADENOSINE ACTION IS INHIBITED BY THE DRUG
|
ALLOPURINOL REDUCES RENAL CLEARANCE OF THE DRUG SO THE DRUG DOSE SHOULD BE REDUCED TO 1/3 OR 1/4
|
DISULFIRAM CHRONIC TREATMENT MAY CAUSE REDUCED METABOLISM OF THE DRUG LEADING TO INCREASED PLASMA LEVELS & PROLONGED HALF LIFE OF THE DRUG
|
CO-ADMINISTRATION IN PATIENTS WHO ARE RECEIVING HIGH DOSES OF THEOPHYLLINE MAY BE ASSOCIATED WITH AN INCREASE IN SERUM THEOPHYLLINE LEVELS AND POTENTIAL THEOPHYLLINE TOXICITY
|
CO-ADMINISTRATION IN PATIENTS WHO ARE RECEIVING HIGH DOSES OF THEOPHYLLINE MAY BE ASSOCIATED WITH AN INCREASE IN SERUM THEOPHYLLINE LEVELS AND POTENTIAL THEOPHYLLINE TOXICITY
|
AMINOPHYLLINE CONCURRENT USE MAY DECREASE ITS HALF LIFE BY 10%
|
CO-ADMINISTRATION IN PATIENTS WHO ARE RECEIVING HIGH DOSES OF THEOPHYLLINE MAY BE ASSOCIATED WITH AN INCREASE IN SERUM THEOPHYLLINE LEVELS AND POTENTIAL THEOPHYLLINE TOXICITY
|
POTENTIAL FOR SEVERE AND FATAL REACTIONS INCLUDING CARDIAC ARREST, SEIZURES, RESPIRATORY FAILURE AND STATUS EPILEPTICUS ; CONCURRENT USE SHOULD BE AVOIDED OR SERUM LEVELS OF THEOPHYLLINE SHOULD BE MONITORED CAREFULLY
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
CONCOMITANT USE SHOULD BE AVOIDED
|
CONCURRENT USE OF MACROLIDES AND THEOPHYLLINE HAS BEEN ASSOCIATED WITH INCREASES IN THE SERUM CONCENTRATION OF THEOPHYLLINE ; THE EFFECT OF AZITHROMYCIN ON THE PLASMA LEVELS OF THEOPHYLLINE ADMINISTERED IN MULTIPLE DOSES IS NOT KNWON
|
CO-ADMINISTRATION IN PATIENTS WHO ARE RECEIVING HIGH DOSES OF THEOPHYLLINE MAY BE ASSOCIATED WITH AN INCREASE IN SERUM THEOPHYLLINE LEVELS AND POTENTIAL THEOPHYLLINE TOXICITY
|
OMEPRAZOLE DELAYS ELIMINATION OF THE DRUG
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
POTENTIAL FOR SEVERE AND FATAL REACTIONS INCLUDING CARDIAC ARREST, SEIZURES, RESPIRATORY FAILURE AND STATUS EPILEPTICUS ; CONCURRENT USE SHOULD BE AVOIDED OR SERUM LEVELS OF THEOPHYLLINE SHOULD BE MONITORED CAREFULLY
|
DECREASED THEOPHYLLINE CLEARANCE
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
POTENTIAL FOR SEVERE AND FATAL REACTIONS INCLUDING CARDIAC ARREST, SEIZURES, RESPIRATORY FAILURE AND STATUS EPILEPTICUS ; CONCURRENT USE SHOULD BE AVOIDED OR SERUM LEVELS OF THEOPHYLLINE SHOULD BE MONITORED CAREFULLY
|
CO-ADMINISTRATION OF QUINOLONES WITH THEOPHYLLINE HAS RESULTED IN ELEVATED PLASMA LEVELS OF THEOPHYLLINE
|
POTENTIAL FOR SEVERE AND FATAL REACTIONS INCLUDING CARDIAC ARREST, SEIZURES, RESPIRATORY FAILURE AND STATUS EPILEPTICUS ; CONCURRENT USE SHOULD BE AVOIDED OR SERUM LEVELS OF THEOPHYLLINE SHOULD BE MONITORED CAREFULLY
|
POTENTIAL FOR SEVERE AND FATAL REACTIONS INCLUDING CARDIAC ARREST, SEIZURES, RESPIRATORY FAILURE AND STATUS EPILEPTICUS ; CONCURRENT USE SHOULD BE AVOIDED OR SERUM LEVELS OF THEOPHYLLINE SHOULD BE MONITORED CAREFULLY
|
ESOMEPRAZOLE INHIBITS GASTRIC ACID SECRETION & MAY INTERFERE WITH THE ABSORPTION OF DRUGS WHERE GASTRIC PH IS AN IMPORTANT DETERMINANT OF BIOAVAILABILITY
|
OMEPRAZOLE DELAYS ELIMINATION OF THE DRUG
|
POTENTIAL FOR SEVERE AND FATAL REACTIONS INCLUDING CARDIAC ARREST, SEIZURES, RESPIRATORY FAILURE AND STATUS EPILEPTICUS ; CONCURRENT USE SHOULD BE AVOIDED OR SERUM LEVELS OF THEOPHYLLINE SHOULD BE MONITORED CAREFULLY
|
POTENTIAL FOR SEVERE AND FATAL REACTIONS INCLUDING CARDIAC ARREST, SEIZURES, RESPIRATORY FAILURE AND STATUS EPILEPTICUS ; CONCURRENT USE SHOULD BE AVOIDED OR SERUM LEVELS OF THEOPHYLLINE SHOULD BE MONITORED CAREFULLY
|